Seroatlas · Human Serome Atlas

S100A6

Protein S100-A6

Also known as: 2A9, CABP, CACY, PRA, S10A6_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P06703
Gene
S100A6
Ensembl
ENSG00000197956
Chromosome
1
Canonical length
90 aa
Protein class
Cancer-related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location
Plasma membrane,Cytosol
Quaternary structure
Homodimer

OverviewNCBI Gene

The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may function in stimulation of Ca2+-dependent insulin release, stimulation of prolactin secretion, and exocytosis. Chromosomal rearrangements and altered expression of this gene have been implicated in melanoma. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

90 residues, UniProt reviewed canonical sequence.

>P06703|S100A6
     1  MACPLDQAIG LLVAIFHKYS GREGDKHTLS KKELKELIQK ELTIGSKLQD AEIARLMEDL
    61  DRNKDQEVNF QEYVTFLGAL ALIYNEALKG

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against S100A6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.37
Highest tissue expression
4,483 nTPM

Expression across tissuesHPA

Tissue

  • blood vessel: 4,483 nTPM
  • urinary bladder: 3,605 nTPM
  • kidney: 3,602 nTPM
  • adipose tissue: 3,468 nTPM
  • lung: 3,315 nTPM
  • colon: 3,077 nTPM

Single-cell type

  • colonocytes: 21,095 nCPM
  • esophageal apical cells: 13,497 nCPM
  • urothelial cells: 11,838 nCPM
  • goblet cells: 11,783 nCPM
  • ocular epithelial cells: 11,436 nCPM
  • gastric progenitor cells: 11,252 nCPM

Immune cell

  • neutrophil: 9,718 nTPM
  • total PBMC: 8,344 nTPM
  • classical monocyte: 6,082 nTPM
  • basophil: 5,552 nTPM
  • myeloid DC: 4,254 nTPM
  • intermediate monocyte: 3,271 nTPM

Brain region

  • hypothalamus: 483 nTPM
  • thalamus: 456 nTPM
  • white matter: 343 nTPM
  • medulla oblongata: 327 nTPM
  • midbrain: 259 nTPM
  • spinal cord: 257 nTPM

ReferencesPubMed · IEDB

Publications for S100A6 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

1 publication

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.64
gnomAD pLI
0.18
gnomAD missense Z
0.25
DepMap mean gene effect
0.01
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of S100A6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads S100A6 as an antibody target. Whether an autoantibody or antibody against S100A6 could matter depends on whether native S100A6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

S100A6 is annotated at the cell surface, where native S100A6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label S100A6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/S100A6. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...